more

Henry Schein (HSIC)

(Real Time Quote from BATS)

$71.87 USD

+1.50 (2.13%)

Updated Nov 4, 2024 11:40 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

Top 40% (101 out of 250)

Industry: Medical - Dental Supplies

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Best Value Stocks to Buy for February 22nd

by Zacks Equity Research Published on February 22,2022

R, SUN, and HSIC made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 22nd, 2022

Best Momentum Stocks to Buy for February 22nd

by Zacks Equity Research Published on February 22,2022

AGCO, HSIC, and MRC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 22, 2022

Abbott (ABT) Gets FDA Approval for CardioMEMS HF System

by Zacks Equity Research Published on February 22,2022

Abbott's (ABT) CardioMEMS HF System will enable physicians to monitor for early warning signs of worsening heart failure before it progresses to a later stage.

Medtronic's (MDT) Cryoablation Catheters Get FDA Expanded Nod

by Zacks Equity Research Published on February 22,2022

Medtronic's (MDT) Cardiac Cryoablation is the only ablation catheter approved to treat pediatric AVNRT.

New Strong Buy Stocks for February 22nd

by Zacks Equity Research Published on February 22,2022

AGCO, WIRE, HSIC, MRC, and NTR have been added to the Zacks Rank #1 (Strong Buy) List on February 22, 2022.

consumer-discretionary

Henry Schein (HSIC) Up 10.1% Since Posting Q4 Earnings Beat

by Zacks Equity Research Published on February 21,2022

Henry Schein (HSIC) stock rallies on strong fourth-quarter performance and bullish 2022 EPS guidance.

Integer Holdings (ITGR) Q4 Earnings, Revenues Top Estimates

by Zacks Equity Research Published on February 18,2022

Integer Holdings' (ITGR) fourth-quarter results reflect robust segmental performances besides strength in the majority of the product lines.

Quidel (QDEL) Q4 Earnings Top Estimates, Margins Decline

by Zacks Equity Research Published on February 18,2022

Despite robust revenues from COVID-19 products, Quidel (QDEL) records an overall soft Q4 performance.

Phibro (PAHC) Up 17.1% Since Q2 Earnings: What's Driving It?

by Zacks Equity Research Published on February 17,2022

Phibro's (PAHC) stock rallies on continued demand for its products globally and raised 2022 guidance.

Illumina's (ILMN) GRAIL, Point32Health Unite to Offer MCED Test

by Zacks Equity Research Published on February 16,2022

Illumina's (ILMN) GRAIL Galleri MCED test detects more than 50 types of cancer and can predict the origin of the cancer signal with high accuracy across multiple cancer types.

Masimo's (MASI) Q4 Earnings Surpass Estimates, Margins Up

by Zacks Equity Research Published on February 16,2022

Masimo's (MASI) robust product shipments, along with strong sensor sales, drive its Q4 sales.

PacBio's (PACB) Q4 Earnings Miss Estimates, Revenues Top

by Zacks Equity Research Published on February 16,2022

PacBio (PACB) sees strength in Q4 segmental revenues, led by robust consumable and instrument sales.

OPKO Health (OPK) to Post Q4 Earnings: What's in the Cards?

by Zacks Equity Research Published on February 15,2022

OPKO Health's (OPK) fourth-quarter results are likely to reflect strength in Rayaldee.

Zimmer Biomet (ZBH) Business Hurt by China VBP, Price Woe

by Zacks Equity Research Published on February 15,2022

According to Zimmer Biomet (ZBH), severe customer staffing shortages and a more-than-anticipated impact of China VBP lead to dismal Q4 revenues.

Phirbo's (PAHC) Dyadic Deal to Fortify Animal Vaccine Wing

by Zacks Equity Research Published on February 15,2022

Per the exclusive agreement, Phirbo (PAHC) together with Dyadic will continue development work to find a vaccine candidate using Dyadic's C1 cells.

Henry Schein (HSIC) Q4 Earnings Top Estimates, Margins Grow

by Zacks Equity Research Published on February 15,2022

Robust performances by all three operating businesses drove Henry Schein's (HSIC) Q4 revenues.

LabCorp (LH) Expands Clinical Laboratory Services With New Pact

by Zacks Equity Research Published on February 15,2022

LabCorp's (LH) recent collaboration will enable it to administer Ascension's hospital-based laboratories in 10 states and purchase select assets of the health system's outreach laboratory business.

Henry Schein (HSIC) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research Published on February 15,2022

Henry Schein (HSIC) delivered earnings and revenue surprises of 18.89% and 4.60%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?